tetano
Editor, Senior Moderator
J Drug Target. 2020 May 13:1-10. doi: 10.1080/1061186X.2020.1769637. [Epub ahead of print]
CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.
Xiang X[SUP]1[/SUP], Qian K[SUP]2[/SUP], Zhang Z[SUP]3[/SUP], Lin F[SUP]1[/SUP], Xie Y[SUP]1[/SUP], Liu Y[SUP]1[/SUP], Yang Z[SUP]1[/SUP].
Author information
Abstract
Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.
KEYWORDS:
COVID-19; CRISPR-Cas; Diagnostics; Infectious diseases
PMID:32401064DOI:10.1080/1061186X.2020.1769637
CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.
Xiang X[SUP]1[/SUP], Qian K[SUP]2[/SUP], Zhang Z[SUP]3[/SUP], Lin F[SUP]1[/SUP], Xie Y[SUP]1[/SUP], Liu Y[SUP]1[/SUP], Yang Z[SUP]1[/SUP].
Author information
Abstract
Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.
KEYWORDS:
COVID-19; CRISPR-Cas; Diagnostics; Infectious diseases
PMID:32401064DOI:10.1080/1061186X.2020.1769637